Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMMA phase II cetuximab study in relapsed or refractory multiple myeloma
ISRCTN81968533Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in multiple myeloma (MM), sponsored by University of Cologne. Primary endpoint: Efficacy of cetuximab. Started Mar 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN81968533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN81968533.